H.C. Wainwright analyst Andrew Fein raised the firm’s price target on KalVista to $24 from $16 and keeps a Buy rating on the shares. The analyst says the company’s sebetralstat delivered a positive on-demand hereditary angioedema profile.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KALV:
